Identification of Symptomatic Fetuses Infected with Cytomegalovirus Using Amniotic Fluid Peptide Biomarkers

PLoS Pathogens

Volumn 12, Issue 1, 2016, Pages

  Desveaux, Cyrille ^a,h   Klein, Julie ^b,c   Leruez Ville, Marianne ^d,e   Ramirez Torres, Adela ^f   Lacroix, Chrystelle ^c,g   Breuil, Benjamin ^b,c   Froment, Carine ^c,g   Bascands, Jean Loup ^b,c   Schanstra, Joost P ^b,c   Ville, Yves ^a,e  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f BURNHAM INSTITUTE   (United States)

^g CNRS   (France)

^h La Reunion University Hospital ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; PEPTIDE; PROTEIN SERINE THREONINE KINASE; VIRUS DNA; VIRAL PROTEIN;

AMINO ACID SEQUENCE; AMNION FLUID; ARTICLE; BRAIN DAMAGE; CAPILLARY ELECTROPHORESIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EVOKED BRAIN STEM AUDITORY RESPONSE; FEMALE; FETUS; FETUS BLOOD SAMPLING; GESTATIONAL AGE; HUMAN; INTRAUTERINE INFECTION; ION CYCLOTRON RESONANCE MASS SPECTROMETRY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PEPTIDOMICS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PREGNANCY TERMINATION; SECOND TRIMESTER PREGNANCY; SEIZURE; SENSITIVITY AND SPECIFICITY; TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS; VIRUS IDENTIFICATION; AMNIOCENTESIS; AREA UNDER THE CURVE; CYTOMEGALOVIRUS INFECTIONS; FETAL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RECEIVER OPERATING CHARACTERISTIC; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

AMNIOCENTESIS; AMNIOTIC FLUID; AREA UNDER CURVE; BIOMARKERS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FETAL DISEASES; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PEPTIDES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; ROC CURVE; SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS;

EID: 84956744808     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005395     Document Type: Article

References (48)

1. Dollard SC, Grosse SD, Ross DS, New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol. 2007;17: 355–63. doi: 10.1002/rmv.544 17542052
2. Kenneson A, Cannon MJ, Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection y. Rev Med Virol. 2007; 253–276. 17579921
3. Benoist G, Leruez-Ville M, Magny JF, Jacquemard F, Salomon LJ, Ville Y, Management of pregnancies with confirmed cytomegalovirus fetal infection. Fetal Diagn Ther. 2013;33: 203–214. doi: 10.1159/000342752 23571413
4. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr. 2001;138: 325–31. doi: 10.1067/mpd.2001.112061 11241037
5. Ancora G, Lanari M, Lazzarotto T, Venturi V, Tridapalli E, Sandri F, et al. Cranial ultrasound scanning and prediction of outcome in newborns with congenital cytomegalovirus infection. J Pediatr. 2007;150: 157–61. doi: 10.1016/j.jpeds.2006.11.032 17236893
6. Lipitz S, Yinon Y, Malinger G, Yagel S, Levit L, Hoffman C, et al. Risk of cytomegalovirus-associated sequelae in relation to time of infection and findings on prenatal imaging. Ultrasound Obstet Gynecol Off J Int Soc Ultrasound Obstet Gynecol. 2013;41: 508–514. doi: 10.1002/uog.12377
7. Farkas N, Hoffmann C, Ben-Sira L, Lev D, Schweiger A, Kidron D, et al. Does normal fetal brain ultrasound predict normal neurodevelopmental outcome in congenital cytomegalovirus infection? Prenat Diagn. 2011;31: 360–366. doi: 10.1002/pd.2694 21413035
8. Benoist G, Salomon LJ, Jacquemard F, Daffos F, Ville Y, The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. BJOG Int J Obstet Gynaecol. 2008;115: 823–829. doi: 10.1111/j.1471-0528.2008.01714.x
9. Fabbri E, Revello MG, Furione M, Zavattoni M, Lilleri D, Tassis B, et al. Prognostic markers of symptomatic congenital human cytomegalovirus infection in fetal blood. BJOG Int J Obstet Gynaecol. 2011;118: 448–456. doi: 10.1111/j.1471-0528.2010.02822.x
10. Goegebuer T, Van Meensel B, Beuselinck K, Cossey V, Van Ranst M, Hanssens M, et al. Clinical predictive value of real-time PCR quantification of human cytomegalovirus DNA in amniotic fluid samples. J Clin Microbiol. 2009;47: 660–665. doi: 10.1128/JCM.01576-08 19109474
11. Guerra B, Lazzarotto T, Quarta S, Lanari M, Bovicelli L, Nicolosi A, et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol. 2000;183: 476–482. doi: 10.1067/mob.2000.106347 10942490
12. Lazzarotto T, Varani S, Guerra B, Nicolosi A, Lanari M, Landini MP, Prenatal indicators of congenital cytomegalovirus infection. J Pediatr. 2000;137: 90–95. doi: 10.1067/mpd.2000.107110 10891828
13. Revello MG, Zavattoni M, Furione M, Baldanti F, Gerna G, Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Microbiol. 1999;37: 3350–3352. 10488204
14. Ville Y, Leruez-Ville M, Managing infections in pregnancy. Curr Opin Infect Dis. 2014;27: 251–257. 24781057
15. Walker SP, Palma-Dias R, Wood EM, Shekleton P, Giles ML, Cytomegalovirus in pregnancy: to screen or not to screen. BMC Pregnancy Childbirth. 2013;13: 96. doi: 10.1186/1471-2393-13-96 23594714
16. Klein J, Buffin-Meyer B, Mullen W, Carty DM, Delles C, Vlahou A, et al. Clinical proteomics in obstetrics and neonatology. Expert Rev Proteomics. 2014;11: 75–89. doi: 10.1586/14789450.2014.872564 24404900
17. Cho C-KJ, Smith CR, Diamandis EP, Amniotic fluid proteome analysis from Down syndrome pregnancies for biomarker discovery. J Proteome Res. 2010;9: 3574–3582. doi: 10.1021/pr100088k 20459121
18. Cho C-KJ, Drabovich AP, Karagiannis GS, Martínez-Morillo E, Dason S, Dimitromanolakis A, et al. Quantitative proteomic analysis of amniocytes reveals potentially dysregulated molecular networks in Down syndrome. Clin Proteomics. 2013;10: 2. doi: 10.1186/1559-0275-10-2 23394617
19. Buhimschi CS, Bhandari V, Hamar BD, Bahtiyar M-O, Zhao G, Sfakianaki AK, et al. Proteomic profiling of the amniotic fluid to detect inflammation, infection, and neonatal sepsis. PLoS Med. 2007;4: e18. doi: 10.1371/journal.pmed.0040018 17227133
20. Buhimschi CS, Bhandari V, Han YW, Dulay AT, Baumbusch MA, Madri JA, et al. Using proteomics in perinatal and neonatal sepsis: hopes and challenges for the future. Curr Opin Infect Dis. 2009;22: 235–243. 19395960
21. Tambor V, Kacerovsky M, Andrys C, Musilova I, Hornychova H, Pliskova L, et al. Amniotic fluid cathelicidin in PPROM pregnancies: from proteomic discovery to assessing its potential in inflammatory complications diagnosis. PloS One. 2012;7: e41164. doi: 10.1371/journal.pone.0041164 22815956
22. Cecconi D, Lonardoni F, Favretto D, Cosmi E, Tucci M, Visentin S, et al. Changes in amniotic fluid and umbilical cord serum proteomic profiles of foetuses with intrauterine growth retardation. Electrophoresis. 2011;32: 3630–3637. doi: 10.1002/elps.201100256 22180211
23. Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J-L, et al. Urine in clinical proteomics. Mol Cell Proteomics MCP. 2008;7: 1850–1862. doi: 10.1074/mcp.R800001-MCP200 18667409
24. Mischak H, Schanstra JP, CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl. 2011;5: 9–23. doi: 10.1002/prca.201000058 21280234
25. Schanstra JP, Mischak H, Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol Berl Ger. 2014; doi: 10.1007/s00467-014-2790-y
26. Romanelli RM de C, Magny JF, Jacquemard F, Prognostic markers of symptomatic congenital cytomegalovirus infection. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2008;12: 38–43.
27. Dreux S, Rousseau T, Gerber S, Col J-Y, Dommergues M, Muller F, Fetal serum beta2-microglobulin as a marker for fetal infectious diseases. Prenat Diagn. 2006;26: 471–474. doi: 10.1002/pd.1441 16652403
28. Kim J-Y, Park S-C, Lee J-K, Choi SJ, Hahm K-S, Park Y, Novel antibacterial activity of β(2)-microglobulin in human amniotic fluid. PloS One. 2012;7: e47642. doi: 10.1371/journal.pone.0047642 23144825
29. Matos ACC, Durão MS, Pacheco-Silva A, Serial beta-2 microglobulin measurement as an auxilliary method in the early diagnosis of cytomegalovirus infection in renal transplant patients. Transplant Proc. 2004;36: 894–895. doi: 10.1016/j.transproceed.2004.03.110 15194307
30. Grundy JE, McKeating JA, Griffiths PD, Cytomegalovirus strain AD169 binds beta 2 microglobulin in vitro after release from cells. J Gen Virol. 1987;68 (Pt 3): 777–784. doi: 10.1099/0022-1317-68-3-777 3029304
31. Vaisbuch E, Romero R, Erez O, Kusanovic JP, Gotsch F, Than NG, et al. Total hemoglobin concentration in amniotic fluid is increased in intraamniotic infection/inflammation. Am J Obstet Gynecol. 2008;199: 426.e1–426.e7. doi: 10.1016/j.ajog.2008.06.075
32. Vanarsdall AL, Johnson DC, Human cytomegalovirus entry into cells. Curr Opin Virol. 2012;2: 37–42. doi: 10.1016/j.coviro.2012.01.001 22440964
33. Chaiworapongsa T, Romero R, Kusanovic JP, Savasan ZA, Kim SK, Mazaki-Tovi S, et al. Unexplained fetal death is associated with increased concentrations of anti-angiogenic factors in amniotic fluid. J Matern-Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Ocean Perinat Soc Int Soc Perinat Obstet. 2010;23: 794–805. doi: 10.3109/14767050903443467
34. Thundyil J, Pavlovski D, Sobey CG, Arumugam TV, Adiponectin receptor signalling in the brain. Br J Pharmacol. 2012;165: 313–327. doi: 10.1111/j.1476-5381.2011.01560.x 21718299
35. Murdoch JN, Damrau C, Paudyal A, Bogani D, Wells S, Greene NDE, et al. Interactions between planar cell polarity genes cause diverse neural tube defects. Dis Model Mech. 2014; doi: 10.1242/dmm.016758
36. Kerfoot C, Wienecke R, Menchine M, Emelin J, Maize JC, Welsh CT, et al. Localization of tuberous sclerosis 2 mRNA and its protein product tuberin in normal human brain and in cerebral lesions of patients with tuberous sclerosis. Brain Pathol Zurich Switz. 1996;6: 367–375.
37. Ha J-Y, Kim J-S, Kang Y-H, Bok E, Kim Y-S, Son JH, Tnfaip8 l1/Oxi-β binds to FBXW5, increasing autophagy through activation of TSC2 in a Parkinson’s disease model. J Neurochem. 2014;129: 527–538. doi: 10.1111/jnc.12643 24444419
38. Cataldi M, The changing landscape of voltage-gated calcium channels in neurovascular disorders and in neurodegenerative diseases. Curr Neuropharmacol. 2013;11: 276–297. doi: 10.2174/1570159X11311030004 24179464
39. Ross S a, Novak Z, Kumbla R a, Zhang K, Fowler KB, Boppana S, GJB2 and GJB6 mutations in children with congenital cytomegalovirus infection. Pediatr Res. 2007;61: 687–91. doi: 10.1203/pdr.0b013e3180536609 17426645
40. Noyola DE, Demmler GJ, Nelson CT, Griesser C, Williamson WD, Atkins JT, et al. Early predictors of neurodevelopmental outcome in symptomatic congenital cytomegalovirus infection. J Pediatr. 2001;138: 325–331. doi: 10.1067/mpd.2001.112061 11241037
41. Klein J, Lacroix C, Caubet C, Siwy J, Zürbig P, Dakna M, et al. Fetal urinary peptides to predict postnatal outcome of renal disease in fetuses with posterior urethral valves (PUV). Sci Transl Med. 2013;5: 198ra106. doi: 10.1126/scitranslmed.3005807 23946195
42. Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 2006;7: 230–240. doi: 10.1016/S1470-2045(06)70584-8 16510332
43. Kolch W, Neusüss C, Pelzing M, Mischak H, Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev. 2005;24: 959–977. doi: 10.1002/mas.20051 15747373
44. Neuhoff N v, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom RCM. 2004;18: 149–156. doi: 10.1002/rcm.1294 14745763
45. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K, Delles C, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res. 2009;8: 268–281. doi: 10.1021/pr800401m 19012428
46. Dakna M, Harris K, Kalousis A, Carpentier S, Kolch W, Schanstra JP, et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010;11: 594. doi: 10.1186/1471-2105-11-594 21208396
47. Klein J, Papadopoulos T, Mischak H, Mullen W, Comparison of CE-MS/MS and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide identification in human urine. Electrophoresis. 2014;35: 1060–1064. doi: 10.1002/elps.201300327 24254231
48. Zürbig P, Renfrow MB, Schiffer E, Novak J, Walden M, Wittke S, et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis. 2006;27: 2111–2125. doi: 10.1002/elps.200500827 16645980